İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2014 · article

Clinical manifestations of 17 patients affected with mucopolysaccharidosis type VI and eight novel ARSB mutations

YÖKSİS OpenAlex
Yıl2014
Atıf23OpenAlex
Atıf23Semantic Scholar · 4 etkili
Yüzdelik%79,1
FWCI1,331,00 = dünya ortalaması
Scopus (SJR)Q2
WoS (JCR)Q3

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıAMERICAN JOURNAL OF MEDICAL GENETICS PART A
  • Katalog eşleşmesi (ISSN)American Journal of Medical Genetics, Part A
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

Mucopolysaccharidosis (MPS) type VI or Maroteaux-Lamy syndrome is a very rare autosomal recessive lysosomal storage disease, caused by a deficiency of the enzyme N-acetylgalactosamine-4-sulfatase (Arylsulfatase B, ARSB). Clinical examination, biochemical studies, and molecular genetic analyses have been performed in 17 patients affected with MPS VI from 15 unrelated families from Thailand, India, and Turkey. Large ear lobule appears to be a newly recognized finding of this syndrome. Mutation analysis of the ARSB gene revealed seven missense and three frameshift mutations of which eight were novel. Novel missense mutations were p.Asp53Asn, p.Val376Glu, p.Glu390Lys, p.Pro445Leu, and p.Trp450Cys, while an Indian patient was homozygous for two novel missense mutations (p.Pro445Leu and p.Trp450Cys). Three novel frameshift mutations were p.Pro70fsX123, p.Ser403fs, and p.Thr526fs. Two previously reported mutations, p.Arg160Gln and p.Leu321Pro, were also observed in our cohort. The amino acid Arg160 appears to be the mutational hot spot for the ARSB gene. Five patients homozygous for p.Leu321Pro mutation had early onset of the disease, and haplotype analysis showed that the mutation is a founder mutation in Turkish population.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

23atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 9 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2015 Prevalence of Anti Adeno Associated Virus Serotype 8 Neutralizing Antibodies and Arylsulfatase B Cross Reactive Immunologic Material in Mucopolysaccharidosis VI Patient Candidates for a Gene Therapy TrialAtıf 31 · OpenAlex
  2. 2021 Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case seriesAtıf 4 · OpenAlex
  3. 2021 Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case seriesAtıf 4 · OpenAlex
  4. 2021 Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case seriesAtıf 4 · OpenAlex
  5. 2021 Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case seriesAtıf 4 · OpenAlex
  6. 2021 Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case seriesAtıf 4 · OpenAlex
  7. 2021 Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case seriesAtıf 4 · OpenAlex
  8. 2019 A Novel Pathological ARSB Mutation (c.870G>A; p.Trp290stop) in Mucopolysaccharidosis Type VI PatientsAtıf 3 · OpenAlex
  9. 2019 Novel Pathological Mutation (c.870 GA, p.Trp290stop) in ARSB of Mucopolysaccharidosis Type VI PatientsAtıf 3 · OpenAlex

Yazarlar

10
  1. PIRANIT NIK KANTAPUTRA 1
  2. HÜLYA KAYSERİLİ KARABEY 2
  3. YELİZ GÜVEN İSTANBUL ÜNİVERSİTESİ 3
  4. WARISSARA KANTAPUTRA 4
  5. MEHMET CİHAN BALCI İSTANBUL ÜNİVERSİTESİ 5
  6. PRANOOT TANPAIBOON 6
  7. NAPAPORN TANANUVAT 7
  8. ANUSHA UTTARILI 8
  9. ASHWIN DALAL 9
  10. MELTEM DEMİREL KARS 10